2012-10-06 19:12:18 - Fast Market Research recommends "Colitis - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Colitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colitis. Colitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468466_colitis_pipeline_review_h2_2012.aspx


Scope

* A snapshot of the global therapeutic scenario for Colitis.
* A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Colitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Colitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Colitis
Colitis Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Colitis Therapeutics - Products under Development by Companies
Companies Involved in Colitis Therapeutics Development
Baxter International Inc.
Inovio Biomedical Corporation
Cytokine PharmaSciences, Inc.
Lpath, Inc.
Resolvyx Pharmaceuticals, Inc
NasVax Ltd.
Dr. Falk Pharma GmbH
Lycera Corp.
Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
sonepcizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-1027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-10001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIF Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-aCD3 Mab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-MIF Antibody - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bioenergetics Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-MIF Receptor Technology Platform - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Colitis Therapeutics - Drug Profile Updates
Colitis Therapeutics - Dormant Products
Colitis - Product Development Milestones
Featured News & Press Releases
Jun 23, 2009: Resolvyx Initiates Phase I Clinical Trial Of Novel Resolvin, RX-10001, For Asthma And Inflammatory Diseases
Mar 18, 2009: ViroPharma Submits Comments on Vancocin Draft Bioequivalence Guidance
Dec 18, 2008: ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin
Dec 15, 2008: ViroPharma Provides Update on Vancocin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Colitis, H2 2012
Products under Development for Colitis - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Baxter International Inc., H2 2012
Inovio Biomedical Corporation, H2 2012
Cytokine PharmaSciences, Inc., H2 2012
Lpath, Inc., H2 2012
Resolvyx Pharmaceuticals, Inc, H2 2012
NasVax Ltd., H2 2012
Dr. Falk Pharma GmbH, H2 2012
Lycera Corp., H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468466&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.